Dominant negative mutants of sam68 for use in the treatment of spinal muscular atrophy (sma)
AssigneeFondazione Santa Lucia
InventorsMaria Paola Paronetto, Simona Pedrotti
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of dominant negative mutants of Sam68 for the manufacture of a medicament for the treatment of spinal muscular atrophy, to nucleic acids coding for such mutants and to vectors and methods related thereto.
Claims14
(canceled)
The method of claim 14, such that survival motor neuron (SMN) protein expression is rescued in the cells of an individual affected by SMA.
The method of claim 14, characterized in that said dominant negative mutant of SEQ. ID. NO:1 comprises at least one amino acid substitution in the region corresponding to amino acids 81 to 276.
The method of claim 14, characterized in that said dominant negative mutant of SEQ. ID. NO:1 comprises at least one amino acid substitution in the region corresponding to amino acids 419 to 443.
The method of claim 14, wherein said dominant negative mutant is a polypeptide of SEQ ID NO:4.
The method of claim 14, wherein said dominant negative mutant of SEQ. ID. NO:1 is encoded by a nucleic acid.
A vector for gene therapy including a nucleic acid encoding for a dominant negative mutant of SEQ ID NO:1.
A dominant negative mutant of SEQ. ID. NO:1 for use in the treatment of SMA.
A method for rescuing survival motor neuron (SMN) protein expression in cells of an individual affected by spinal muscular atrophy for the treatment of SMA comprising administering a dominant negative mutant Sam68 polypeptide and/or nucleic acid to said cells.
The method of claim 12, wherein said dominant negative mutant of SEQ ID NO:1 is a dominant negative mutant according to claim 14.
A method of treating SMA comprising use of a dominant negative mutant of SEQ. ID. NO:1.
Dependencies are inferred from the claim text.